momentum: momelotinib vs danazol in r/r myelofibrosis
Published 2 years ago • 336 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:12
momentum: momelotinib vs danazol in myelofibrosis
-
1:20
overview & updates on the momentum trial comparing momelotinib and danazol in myelofibrosis
-
1:04
long-term survival outcomes in pts with mf treated with momelotinib vs danazol in the momentum trial
-
40:16
momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (momentum)
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
1:24
updated results from the momentum study assessing the efficacy of momelotinib in mf
-
2:20
momentum & the potential impact of approval of momelotinib in myelofibrosis
-
3:03
an insight into the momentum trial: safety and efficacy of momelotinib for the treatment of mf
-
32:23
managing mf - dr. srdan verstovsek
-
4:36
being marilyn…with myelofibrosis—an mf journey
-
6:52
long-term follow-up of allogeneic stem cell transplantation with omidubicel
-
3:00
the promise of momelotinib in the treatment of myelofibrosis
-
3:43
momelotinib: a promising drug for patients with myelofibrosis
-
1:53
recent updates from the momentum trial and the value of momelotinib for the treatment of mf
-
2:48
updated results from the momentum trial
-
2:26
assessing the impact of momelotinib on transfusion burden in mf: analysis of simplify-1 & momentum
-
2:53
long-term safety of momelotinib in myelofibrosis: pooled data from three phase iii randomized trials
-
4:15
the latest data on momelotinib for mpns
-
2:21
clinical updates on the use of momelotinib for mpns
-
1:30
results of the ruxopeg trial: combining ruxolitinib and interferon in patients with myelofibrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy